Assessment of MDM2 Gene Locus Amplification by Fluorescence In-Situ Hybridization in Juvenile Ossifying Fibroma.
Benign fibro-osseous
Juvenile Ossifying Fibroma
Low-grade Intramedullary Osteosarcoma, FISH
MDM2
Osteosarcoma
Journal
Head and neck pathology
ISSN: 1936-0568
Titre abrégé: Head Neck Pathol
Pays: United States
ID NLM: 101304010
Informations de publication
Date de publication:
06 Aug 2024
06 Aug 2024
Historique:
received:
30
06
2024
accepted:
20
07
2024
medline:
6
8
2024
pubmed:
6
8
2024
entrez:
6
8
2024
Statut:
epublish
Résumé
Juvenile ossifying fibroma (JOF) is an uncommon benign fibro-osseous lesion (BFOL) of the maxillofacial bones with a locally aggressive nature and a high recurrence rate. Murine Double Minute 2 (MDM2) is an oncogene located at chromosome 12 (12q13-15) that inhibits the tumor suppressor gene TP53. The presence of MDM2 gene locus amplification is a useful molecular adjunct in the evaluation of some sarcomas, including low-grade intramedullary osteosarcoma (LGIOS). JOF and LGIOS have some overlapping clinical and histopathological features. The aim of this study is to evaluate a series of JOF for the presence of MDM2 gene locus amplification using fluorescence in-situ hybridization (FISH). With IRB approval, a search of the institutional files of the archives of the Oral Pathology and Surgical Pathology biopsy services at the University of Florida Health was performed. The cases were re-evaluated by an oral pathology resident, an oral and maxillofacial pathologist, and a bone and soft tissue pathologist. Cases with consensus in diagnosis were selected (n = 9) for MDM2 testing. Testing by FISH for MDM2 gene locus amplification was applied to all retrieved cases. The examined cases were all negative for MDM2 gene locus amplification via FISH testing. In our small series, JOF did not demonstrate MDM2 gene locus abnormality, a characteristic of LGIOS. This finding suggests that JOF has a distinct underlying pathogenesis. If confirmed in a larger series, these findings may be useful in distinguishing these two entities in cases with overlapping features or when minimal biopsy material is available.
Identifiants
pubmed: 39105970
doi: 10.1007/s12105-024-01682-x
pii: 10.1007/s12105-024-01682-x
doi:
Substances chimiques
Proto-Oncogene Proteins c-mdm2
EC 2.3.2.27
MDM2 protein, human
EC 2.3.2.27
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
71Informations de copyright
© 2024. The Author(s).
Références
Slootweg P, El-Mofty S (2005) Ossifying Fibroma. In: Barnes L, Eveson J, Reichart P, Sidronsky D (eds) Pathology and genetics head and neck tumors. IARC, Lyon, pp 319–320
El-Mofty S (2002) Psammomatoid and trabecular juvenile ossifying fibroma of the craniofacial skeleton: two distinct clinicopathologic entities. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 93(3):296–304
doi: 10.1067/moe.2002.121545
pubmed: 11925539
Slootweg PJ, Muller H (1990) Juvenile ossifying fibroma. Report of four cases. J Craniomaxillofac Surg 18(3):125–129
doi: 10.1016/S1010-5182(05)80329-4
pubmed: 2345185
Slootweg PJ, Panders AK, Koopmans R, Nikkels PG (1994) Juvenile ossifying fibroma. An analysis of 33 cases with emphasis on histopathological aspects. J Oral Pathol Med 23(9):385–388
doi: 10.1111/j.1600-0714.1994.tb00081.x
pubmed: 7823298
Margo CE, Weiss A, Habal MB (1986) Psammomatoid ossifying fibroma. Arch Ophthalmol 104(9):1347–1351
doi: 10.1001/archopht.1986.01050210101034
pubmed: 3753286
El-Mofty S (2009) Bone lesions. In: Gnepp D (ed) Diagnostic surgical pathology of the head and neck, 2nd edn. Saunders, Elsevier, Philadelphia, pp 729–784
doi: 10.1016/B978-1-4160-2589-4.00009-7
Tabatabaei SH, Jahanshahi G, Dehghan Marvasti F (2015) Diagnostic challenges of low-grade central osteosarcoma of jaw: a literature review. J Dent (Shiraz) 16(2):62–67
pubmed: 26046099
Fletcher C, Unni KK, Mertens F (2004) World Health Organisation Classification Pathology and Genetics. Tumours of the soft tissue and bone. IARC, Lyon, France
Kurt AM, Unni KK, McLeod RA et al (1990) Low-grade intraosseous osteosarcoma. Cancer 65:1418–1428
doi: 10.1002/1097-0142(19900315)65:6<1418::AID-CNCR2820650629>3.0.CO;2-Q
pubmed: 2306687
Zhao Y, Yu H, Hu W (2014) The regulation of MDM2 oncogene and its impact on human cancers. Acta Biochim Biophys Sin (Shanghai) 46(3):180–189. https://doi.org/10.1093/abbs/gmt147
doi: 10.1093/abbs/gmt147
pubmed: 24389645
Momand J, Jung D, Wilczynski S, Niland J (1998) The MDM2 gene amplification database. Nucleic Acids Res 26:3453–3459. https://doi.org/10.1093/nar/26.15.3453
doi: 10.1093/nar/26.15.3453
pubmed: 9671804
pmcid: 147746
Mejia-Guerrero S, Quejada M, Gokgoz N, Gill M, Parkes RK, Wunder JS, Andrulis IL (2010) Characterization of the 12q15 MDM2 and 12q13-14 CDK4 amplicons and clinical correlations in osteosarcoma. Genes Chromosomes Cancer. ;49(6):518 – 25. https://doi.org/10.1002/gcc.20761 . PMID: 20196171
Cleven AHG, Schreuder WH, Groen E, Kroon HM, Baumhoer D (2020) Molecular findings in maxillofacial bone tumours and its diagnostic value. Virchows Arch. ;476(1):159–174. doi: 10.1007/s00428-019-02726-2. Epub 2019 Dec 14. PMID: 31838586; PMCID: PMC6968989
Grimer RJ, Carter SR, Spooner D et al (2001) Diagnosing musculoskeletal tumours. Sarcoma 5:89–94
doi: 10.1155/S1357714X01000172
pubmed: 18521309
pmcid: 2395457
Mankin HJ, Lange TA, Spanier SS (1982) The hazards of biopsy in patients with malignant primary bone and soft tissue tumours. J Bone Joint Surg 64:1121–1127
doi: 10.2106/00004623-198264080-00002
pubmed: 7130225
Sawyer JR, Tryka AF, Bell JM et al (1995) Nonrandom chromosome breakpoints at Xq26 and 2q33 characterize cemento-ossifying fibromas of the orbit. Cancer 76:1853–1859
doi: 10.1002/1097-0142(19951115)76:10<1853::AID-CNCR2820761026>3.0.CO;2-D
pubmed: 8625058
Tabareau-Delalande F, Collin C, Gomez-Brouchet A, Bouvier C, Decouvelaere A-V et al (2014) Chromosome 12 long arm rearrangement covering MDM2 and RASAL1 is associated with aggressive craniofacial juvenile ossifying fibroma and extracranial psammomatoid fibro-osseous lesions. Mod Pathol. https://doi.org/10.1038/modpathol.2014.80
doi: 10.1038/modpathol.2014.80
pubmed: 24925056
Dujardin F, Binh MB, Bouvier C, Gomez-Brouchet A, Larousserie F, Muret Ad, Louis-Brennetot C, Aurias A, Coindre JM, Guillou L, Pedeutour F, Duval H, Collin C, de Pinieux G (2011) MDM2 and CDK4 immunohistochemistry is a valuable tool in the differential diagnosis of low-grade osteosarcomas and other primary fibro-osseous lesions of the bone. Mod Pathol 24(5):624–637. https://doi.org/10.1038/modpathol.2010.229 Epub 2011 Feb 18. PMID: 21336260
doi: 10.1038/modpathol.2010.229
pubmed: 21336260
Kansara M, Teng MW, Smyth MJ, Thomas DM (2014) Translational biology of osteosarcoma. Nat Rev Cancer. ;14(11):722 – 35. https://doi.org/10.1038/nrc3838 . Epub 2014 Oct 16. PMID: 25319867
Nikitakis NG, Georgaki M, Merkourea S, Chaisuparat R, Warburton G, Lopes MA, Papadimitriou JC, Ord RA (2022) Juvenile trabecular ossifying fibroma: immunohistochemical expression of MDM2, CDK4 and p53 compared to conventional ossifying fibroma. J Clin Exp Dent 14(1):e27–e34. https://doi.org/10.4317/jced.59116 PMID: 35070121; PMCID: PMC8760962
doi: 10.4317/jced.59116
pubmed: 35070121
pmcid: 8760962